Inhibikase Therapeutics Inc (IKT)
$2.35
$0.02
(0.64%)
As on 11-Sep-2026 11:35EDT
Market cap
$349 Mln
Revenue (TTM)
$0 Mln
P/E Ratio
--
P/B Ratio
2.2
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$0 Mln
-
ROE
-0.5 %
-
ROCE
-- %
-
Industry P/E
--
-
EV/EBITDA
0.3
-
Debt to Equity
0
-
Book Value
$--
-
EPS
$-0.5
-
Face value
--
-
Shares outstanding
139,535,900
8 Years Aggregate
CFO
$-50.64 Mln
EBITDA
$-63.44 Mln
Net Profit
$-62.52 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Inhibikase Therapeutics Inc (IKT)
| 14.4 | -4.7 | 41.3 | 52.3 | 5.1 | -29.8 | -- |
|
BSE Sensex
| -11.7 | -4.8 | 1.1 | -8.2 | 3.9 | 5.1 | 10.0 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
|---|---|---|---|---|---|
|
Inhibikase Therapeutics Inc (IKT)
| -36.9 | 154.0 | -57.7 | -66.0 | -78.7 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | -17.4 | 25.3 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Inhibikase Therapeutics Inc (IKT)
|
2.3 | 348.8 | 0.0 | -60.6 | -- | -37.2 | -- | 2.2 |
| 84.6 | 12,161.6 | 669.5 | -320.0 | -0.8 | -71.1 | -- | 26.2 | |
| 262.1 | 17,746.8 | 1,054.4 | 755.9 | 5.7 | -- | 20.9 | 10.5 | |
| 74.6 | 10,109.8 | 71.0 | -894.0 | -1,175.8 | -- | -- | 60.5 | |
| 56.1 | 14,621.6 | 2,435.9 | 860.6 | 31.0 | 43 | 18.6 | 7.9 | |
| 107.1 | 12,506.3 | 1,663.7 | 413.6 | 36.3 | 430 | 32.3 | 86.7 | |
| 350.5 | 10,603.5 | 440.5 | 241.5 | 33.4 | 18.7 | 44.9 | 8.1 | |
| 535.7 | 12,501.2 | 1,283.9 | -325.1 | -19.0 | -57.7 | -- | 23.9 | |
| 593.8 | 16,503.9 | 2,782.3 | 491.5 | 21.1 | 110.1 | 34.7 | 38.2 | |
| 339.1 | 9,822.5 | 0.0 | -339.1 | -- | -30.6 | -- | 7.4 |
Shareholding Pattern
View DetailsAbout Inhibikase Therapeutics Inc (IKT)
Inhibikase Therapeutics, Inc. operates as a clinical-stage pharmaceutical company that develops therapeutics to modify the course of cardiopulmonary diseases, with a primary focus on pulmonary arterial hypertension (PAH), a progressive,... life-threatening disease characterized by pulmonary vascular remodeling and elevated pulmonary vascular resistance. It offers IKT-001, a novel oral prodrug of imatinib mesylate designed for the treatment of pulmonary arterial hypertension (PAH) was designed to improve areas of the molecule that might play a role in the gastrointestinal side effects associated with imatinib, while maintaining systemic exposure and efficacy through oral administration. The company has completed non-human primate safety studies and a bioequivalence clinical study in healthy volunteers, establishing dose equivalence with imatinib. IKT-001 is currently being evaluated in a global, adaptive Phase 3 clinical trial (IMPROVE-PAH), with endpoints including pulmonary vascular resistance and 6-minute walk distance. Inhibikase Therapeutics, Inc. entered into a collaborative research and development agreement with Sphaera Pharma Pte. Ltd., which was subsequently assigned to Pivot Holding LLC, for prodrug technology development and maintains an exclusive license for IKT-001. The company was founded in 2008 and is headquartered in Wilmington, Delaware. Read more
-
CEO, President & Director
Dr. Milton H. Werner Ph.D.
-
CEO, President & Director
Dr. Milton H. Werner Ph.D.
-
Headquarters
Wilmington, DE
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for Inhibikase Therapeutics Inc (IKT)
What is the current share price of Inhibikase Therapeutics Inc (IKT) Today?
The share price of Inhibikase Therapeutics Inc (IKT) is $2.35 (NASDAQ) as of 11-Sep-2026 11:35 EDT. Inhibikase Therapeutics Inc (IKT) has given a return of 5.1% in the last 3 years.
What is the current PB & PE ratio of Inhibikase Therapeutics Inc (IKT)?
Since, TTM earnings of Inhibikase Therapeutics Inc (IKT) is negative, P/E ratio is not available.
The P/B ratio of Inhibikase Therapeutics Inc (IKT) is 2.17 times as on 04-Sep-2026, a 59 discount to its peers’ median range of 5.33 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
2025 |
-4.00 |
1.12 |
2024 |
-1.92 |
0.56 |
2023 |
-0.41 |
0.72 |
2022 |
-0.12 |
0.10 |
2021 |
-0.42 |
0.16 |
What is the 52 Week High and Low of Inhibikase Therapeutics Inc (IKT)?
The 52-week high and low of Inhibikase Therapeutics Inc (IKT) are Rs 2.61 and Rs 1.33 as of 11-Sep-2026.
What is the market cap of Inhibikase Therapeutics Inc (IKT)?
Inhibikase Therapeutics Inc (IKT) has a market capitalisation of $ 349 Mln as on 04-Sep-2026. As per SEBI classification, it is a Small Cap company.
Should I invest in Inhibikase Therapeutics Inc (IKT)?
Before investing in Inhibikase Therapeutics Inc (IKT), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.